登录 | 注册    关注公众号  
微信公众号
搜索
 >  Kits>IL-10 >CRS-B005

ClinMax™ Human IL-10 ELISA Kit

For research use only.

产品概述(Product Details)

ClinMax™ Human IL-10 ELISA Kit is a ready-to-use immunoassay kit, specifically designed to quantitate natural and recombinant human IL-10 that is present in biological samples, such as human serum, plasma, and cell culture supernatants. Our ClinMax™ ELISA Kit provides several benefits:

  1. Standards to calibrate with NIBSC/WHO standards for comparable results.
  2. Fully validation in biologic samples for detection range, sensitivity, inter- and intra-plate CV, recovery, dilution linearity, specificity, and matrix effects to ensure reliable results according to ICH M10 guideline.
  3. High-quality antibody pairs and protein standards, along with rigorous quality control, to guarantee consistent results across different batches.
  4. Simplified and straightforward protocols and ready-to-use reagents to save assay time.

应用说明(Application)

The kit is developed for quantitative detection of natural and recombinant human IL-10 in serum, plasma and cell culture supernatants.

It is for research use only.

流程图(Workflow)

IL-10 Workflow

关键信息(Key Features)

Assay TypeSandwich-ELISA
AnalyteIL-10
Format96-wells plate breakable into 12 x 8 wells strips
ReactivityHuman
Sensitivity2.0 pg/mL
Assay Time1.75 hr
Sample volume50 uL
Range4.12 pg/mL-1000 pg/mL
Sample TypeCell Culture Supernatants, Plasma, Serum.
NIBSC Code93/722

Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.

存储(Storage)

Unopened kit should be stored at 2℃-8℃ upon receiving. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

典型数据-Typical Data Please refer to DS document for the assay protocol.

IL-10 TYPICAL DATA

For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of IL-10 is less than 2.0 pg/mL.

 

验证(Validation)

样本值(Sample Values)

Serum Sample – 240 samples from healthy volunteers were tested for the presence of human IL-10 concentration in the assay. 238 samples were detectable. No medical histories were available for the donors used in this study.

IL-10 SAMPLE VALUES

Cell Culture Supernatant – Human peripheral blood mononuclear cells (PBMCs) were cultured and stimulated with target cells at E:T ratios of 1:10 and 1:5, and then detect the secretion of IL-10 under stimulation with different concentrations of Blinatumomab.

IL-10 SAMPLE VALUES

基质效应(Matrix Effect)

6 types of materials were tested to observe if there were matrix effect (interference). If the concentration of hemoglobin (simulated hemolysis) is less than 3500 mg/dL, the concen-tration of triglyceride (simulated lipid blood) is less than 2.0 g/L, the concentration of bili-rubin (simulated jaundice) is less than 20 mg/dL, Heparin concentration is less than 40 U/mL, EDTA concentration is less than 4 mg/mL, and Sodium Citrate Plasma concentration is less than 40 mg/mL, testing results will not be affected.

IL-10 MATRIX EFFECT

稀释线性(Dilution Linearity)

High concentrations of human IL-10 serum samples were diluted with 1:2, 1:4, and 1:8 ratios for gradient dilution to evaluate the linearity of the assay. In the serum samples, the average detection rate of IL-10 was 100.67%.

IL-10 DILUTION LINEARITY

批内差异(Intra-Assay Statistics)

10 replicates of each of 3 samples containing different IL-10 concentrations were tested in one assay. Acceptable criteria: CV<10%.

IL-10 INTRA-ASSAY STATISTICS

批间差异(Inter-Assay Statistics)

3 samples containing different concentrations of IL-10 were tested in the independent as-says. Acceptable criteria: CV<15%.

IL-10 INTER-ASSAY STATISTICS

回收率(Recovery)

IL-10 was spiked into 5 human serum samples, and then analyzed. The average recovery of IL-10 for serum samples is 100.67%.

IL-10 RECOVERY

 

组分(Materials Provided)

IDComponentsSize
CRB005-C01Pre-coated Anti-IL-10 Antibody Microplate1 plate
CRB005-C02Human IL-10 Standard60 μg×2
CRB005-C03Biotin-Anti-IL-10 Antibody Con. Solution100 μL
CRB005-C04Biotin-Antibody Dilution Buffer8 mL
CRB005-C05Streptavidin-HRP Con. Solution500 μL
CRB005-C06Streptavidin-HRP Dilution Buffer15 mL
CRB005-C0720× Washing Buffer50 mL
CRB005-C081× Dilution Buffer15 mL×2
CRB005-C09Substrate Solution12 mL
CRB005-C10Stop Solution6 mL

 
评论(1)
  1. 139XXXXXXX3
  2. 0人赞
  3. 使用试剂盒定量检测血清中的白介素10。方便快捷,并且结果很稳定,重复性好,满足了做验证的精确度准确度,可靠性高。
  4. 2023-11-22
 
ACRO质量管理体系
 
 

前沿进展

Ascl1-mediated enhancement of GABAergic neuronal function in differentiated F11 cells under high glucose conditions
Go, Park, Yum et al
Biochem Biophys Res Commun (2025) 760, 151721
Abstract: Gamma-aminobutyric acid (GABA)ergic neurons play a key role in pain modulation within the dorsal root ganglion (DRG), making them critical targets for therapeutic studies. This study utilized F11 cells as an in vitro model to examine GABAergic function under high-glucose conditions mimicking diabetic neuropathy. Differentiated F11 cells exhibited increased sensory neuronal marker expression and functional action potentials. Overexpression of the transcription factor Achaete-scute homolog 1 (Ascl1) via lentiviral vectors enhanced GABAergic characteristics, including upregulation of GAD65, GAD67, VGAT, and GABA release. Under high-glucose conditions, Ascl1 modulated pro-inflammatory cytokines (TNF-α, NF-κB, IL-1β), anti-inflammatory cytokines (IL-4, IL-10), and pain-related channels (TRPV1, TRPA1, Nav1.8), reversing pathological changes. Temporal control of Ascl1 during differentiation reduced hypersensitivity and improved cell viability, mediated by parvalbumin in a specific GABAergic subtype. These findings highlight the therapeutic potential of Ascl1 in neuropathic pain and the scalability of F11 cells for high-throughput screening of GABAergic therapeutics.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Antibacterial collagen-guar gum hydrogels with zeolitic imidazolate framework-67 (ZIF-67): an innovative platform for advanced wound healing
Hernandez-Urquizo, Claudio Rizo, Cabrera-Munguía et al
J Biomater Sci Polym Ed (2025)
Abstract: The current challenge in developing wound healing dressings lies in achieving antibacterial effects while avoiding cytotoxicity to cells that are crucial for the healing process. Addressing this challenge, Zeolitic Imidazolate Framework-67 (ZIF-67), a cobalt-containing metal-organic framework (MOF), has emerged as a promising additive due to cobalt's broad-spectrum antimicrobial effects. This study developed semi-interpenetrating polymer network (semi-IPN) hydrogels by incorporating 1-3 wt.% ZIF-67 into collagen-guar gum matrices, resulting in biocomposites with tunable structural and functional properties. These biocomposites exhibit a fibrillar-granular morphology, uniform cobalt ion distribution on a semi-crystalline surface, and strong antibacterial activity against Escherichia coli (E. coli). At 3 wt.%, ZIF-67 accelerates gelation, strengthens crosslinking interactions, and enhances the storage modulus, thermal stability, and hydrolytic resistance of the hydrogels. Furthermore, biocomposites with 1 wt.% ZIF-67 also function as in-situ curcumin delivery systems, offering controlled release under physiological conditions and significant biodegradation in the presence of collagenase. In vitro tests demonstrate that the chemical composition of these hydrogels, regardless of ZIF-67 content, effectively supports monocyte and fibroblast metabolic activity, promotes cell proliferation, and increases interleukin-10 (IL-10) secretion by human monocytes. Additionally, the absence of hemolytic effects in human blood further underscores the safety and suitability of these hydrogel biocomposites for advanced wound treatment applications.
Microbiota-dependent modulation of intestinal anti-inflammatory CD4+ T cell responses
Edwards, Brockmann
Semin Immunopathol (2025) 47 (1), 23
Abstract: Barrier organs such as the gastrointestinal tract, lungs, and skin are colonized by diverse microbial strains, including bacteria, viruses, and fungi. These microorganisms, collectively known as the commensal microbiota, play critical roles in maintaining health by defending against pathogens, metabolizing nutrients, and providing essential metabolites. In the gut, commensal-derived antigens are frequently sensed by the intestinal immune system. Maintaining tolerance toward these beneficial microbial species is crucial, as failure to do so can lead to chronic inflammatory conditions like inflammatory bowel disease (IBD) and can even affect systemic immune or metabolic health. The immune system carefully regulates responses to commensals through various mechanisms, including the induction of anti-inflammatory CD4⁺ T cell responses. Foxp3⁺ regulatory T cells (Foxp3+ Tregs) and Type 1 regulatory T cells (Tr1) play a major role in promoting tolerance, as both cell types can produce the anti-inflammatory cytokine IL-10. In addition to these regulatory T cells, effector T cell subsets, such as Th17 cells, also adopt anti-inflammatory functions within the intestine in response to the microbiota. This process of anti-inflammatory CD4+ T cell induction is heavily influenced by the microbiota and their metabolites. Microbial metabolites affect intestinal epithelial cells, promoting the secretion of anti-inflammatory mediators that create a tolerogenic environment. They also modulate intestinal dendritic cells (DCs) and macrophages, inducing a tolerogenic state, and can interact directly with T cells to drive anti-inflammatory CD4⁺ T cell functionality. The disrupted balance of these signals may result in chronic inflammation, with broader implications for systemic health. In this review, we highlight the intricate interplays between commensal microorganisms and the immune system in the gut. We discuss how the microbiota influences the differentiation of commensal-specific anti-inflammatory CD4⁺ T cells, such as Foxp3⁺ Tregs, Tr1 cells, and Th17 cells, and explore the mechanisms through which microbial metabolites modulate these processes. We further discuss the innate signals that prime and commit these cells to an anti-inflammatory fate.© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Immunomodulatory Properties of Live and Thermally-Inactivated Food-Origin Lactic Acid Bacteria-In Vitro Studies
Mosiej, Długosz, Kruk et al
Mol Nutr Food Res (2025)
Abstract: The study investigates the strain-specific immunomodulatory properties of live and thermally-inactivated (TI) lactic acid bacteria (LAB) derived from traditional Polish fermented foods, focusing on their potential as probiotics and postbiotics. LAB strains, known for their role in food fermentation, were assessed for their ability to influence cytokine production in THP-1 macrophages, maintain intestinal epithelial barrier integrity in Caco-2 monolayers, exhibit antioxidant activity, and produce specific organic acids and sugars. The research demonstrated that live LAB strains significantly upregulated the anti-inflammatory cytokine IL-10, particularly under inflammatory conditions, while TI strains exhibited notable antioxidant and anti-inflammatory properties. TI strains showed a greater ability to protect epithelial barrier function and reduce pro-inflammatory cytokine secretion than live strains, suggesting a promising role for postbiotics. The findings underscore the potential of LAB from fermented foods, demonstrating that postbiotic derivatives can differently influence inflammation compared to live bacteria, highlighting their potential as immune-enhancing agents, capable of modulating immune responses and offering therapeutic benefits against inflammation-related disorders. However, the limitations of in vitro models highlight the need for further in vivo and clinical studies to validate these effects and fully uncover the health benefits of these LAB strains for humans.© 2025 Wiley‐VCH GmbH.
Showing 1-4 of 87348 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IL-10靶点信息
英文全称:Interleukin-10
中文全称:白细胞介素-10
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:6详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细
相关产品
View All IL-10

消息提示

请输入您的联系方式,再点击提交!

确定